The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction

  • Choi, Ki Hong (Department of Medicine, Sungkyunkwan University School of Medicine) ;
  • Lee, Ga Yeon (Department of Medicine, Sungkyunkwan University School of Medicine) ;
  • Choi, Jin-Oh (Department of Medicine, Sungkyunkwan University School of Medicine) ;
  • Jeon, Eun-Seok (Department of Medicine, Sungkyunkwan University School of Medicine) ;
  • Lee, Hae-Young (Department of Internal Medicine, Seoul National University Hospital) ;
  • Lee, Sang Eun (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Kim, Jae-Joong (Department of Internal Medicine, University of Ulsan College of Medicine) ;
  • Chae, Shung Chull (Department of Internal Medicine, School of Medicine, Kyungpook National University) ;
  • Baek, Sang Hong (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kang, Seok-Min (Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Choi, Dong-Ju (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Yoo, Byung-Su (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Kim, Kye Hun (Heart Research Center of Chonnam National University) ;
  • Cho, Myeong-Chan (Department of Internal Medicine, Chungbuk National University College of Medicine) ;
  • Park, Hyun-Young (National Institute of Health (NIH)) ;
  • Oh, Byung-Hee (Department of Internal Medicine, Seoul National University Hospital)
  • Received : 2018.01.06
  • Accepted : 2018.04.02
  • Published : 2019.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: It is unknown whether different β-blockers (BBs) have variable effects on long-term survival of patients with heart failure with reduced ejection fraction (HFrEF). This study compares the effects of two BBs, carvedilol and bisoprolol, on survival in patients with HFrEF. Methods: The Korean Acute Heart Failure (KorAHF) registry is a prospective multicenter cohort that includes 5,625 patients who were hospitalized for acute heart failure (AHF). We selected 3,016 patients with HFrEF and divided this study population into two groups: BB at discharge (n = 1,707) or no BB at discharge (n = 1,309). Among patients with BB at discharge, subgroups were formed based on carvedilol prescription (n = 831), or bisoprolol prescription (n = 553). Propensity score matching analysis was performed. Results: Among patients who were prescribed a BB at discharge, 60.5% received carvedilol and 32.7% received bisoprolol. There was a significant reduction in allcause mortality in those patients with HFrEF prescribed a BB at discharge compared to those who were not (BB vs. no BB, 26.1% vs. 40.8%; hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.52 to 0.67; p < 0.001). However, there was no significant difference in the rate of all-cause mortality between those receiving different types of BB (carvedilol vs. bisoprolol, 27.5% vs. 23.5%; HR, 1.21; 95% CI, 0.99 to 1.47; p = 0.07). Similar results were observed after propensity score matching analysis (508 pairs, 26.2% vs. 23.8%; HR, 1.10; 95% CI, 0.86 to 1.40; p = 0.47). Conclusions: In the treatment of AHF with reduced EF after hospitalization, mortality benefits of carvedilol and bisoprolol were comparable.

Keywords

Acknowledgement

This work was supported by the Research of Korea Centers for Disease Control and Prevention (2010-E63003-00, 2011-E63002- 00, 2012-E63005-00, 2013-E63003-00, 2013-18 E63003-01, 2013- E63003-02, and 2016-ER6303-00).

References

  1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200. https://doi.org/10.1093/eurheartj/ehw128
  2. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239. https://doi.org/10.1016/j.jacc.2013.05.019
  3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007. https://doi.org/10.1016/S0140-6736(99)04440-2
  4. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. https://doi.org/10.1016/S0140-6736(98)11181-9
  5. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355. https://doi.org/10.1056/NEJM199605233342101
  6. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199. https://doi.org/10.1161/01.CIR.0000035653.72855.BF
  7. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825. https://doi.org/10.1161/01.CIR.94.11.2817
  8. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. https://doi.org/10.1016/S0140-6736(03)13800-7
  9. Pasternak B, Svanstrom H, Melbye M, Hviid A. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure. JAMA Intern Med 2014;174:1597-1604. https://doi.org/10.1001/jamainternmed.2014.3258
  10. Frohlich H, Torres L, Tager T, et al. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol 2017;106:711-721. https://doi.org/10.1007/s00392-017-1115-0
  11. Frohlich H, Zhao J, Tager T, et al. Carvedilol compared with metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure: carvedilol or metoprolol evaluation study. Circ Heart Fail 2015;8:887-896. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001701
  12. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907. https://doi.org/10.1067/mhj.2001.115584
  13. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55. https://doi.org/10.1136/bmj.f55
  14. Lee SE, Lee HY, Cho HJ, et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure registry (KorAHF). Korean Circ J 2017;47:341-353. https://doi.org/10.4070/kcj.2016.0419
  15. Lee SE, Cho HJ, Lee HY, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. Eur J Heart Fail 2014;16:700-708. https://doi.org/10.1002/ejhf.91
  16. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367. https://doi.org/10.1016/S0894-7317(89)80014-8
  17. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254. https://doi.org/10.7326/0003-4819-145-4-200608150-00004
  18. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004;147:324-330. https://doi.org/10.1016/j.ahj.2003.07.023
  19. Di Lenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999;33:1926-1934. https://doi.org/10.1016/S0735-1097(99)00134-5
  20. Fonarow GC, Abraham WT, Albert NM, et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007;153:82.
  21. Hori M, Nagai R, Izumi T, Matsuzaki M. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study. Heart Vessels 2014;29:238-247. https://doi.org/10.1007/s00380-013-0340-3
  22. Bolling R, Scheller NM, Kober L, Poulsen HE, Gislason GH, Torp-Pedersen C. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur J Heart Fail 2014;16:678-684. https://doi.org/10.1002/ejhf.81
  23. Konishi M, Haraguchi G, Kimura S, et al. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ J 2010;74:1127-1134. https://doi.org/10.1253/circj.CJ-09-0989
  24. Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006;47:2462-2469. https://doi.org/10.1016/j.jacc.2006.03.030
  25. Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 2007;9:901-909. https://doi.org/10.1016/j.ejheart.2007.05.011
  26. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008;52:190-199. https://doi.org/10.1016/j.jacc.2008.03.048
  27. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M; IMPACT-HF Investigators and Coordinators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-1541. https://doi.org/10.1016/j.jacc.2003.12.040

Cited by

  1. Perspective on the Role of Four Beta-blockers in Heart Failure vol.16, 2021, https://doi.org/10.2174/2772432816666211029103324
  2. Current concept in the diagnosis, treatment and rehabilitation of patients with congestive heart failure vol.13, pp.7, 2019, https://doi.org/10.4330/wjc.v13.i7.183